Understanding the Impact of Diabetes Remission on Healthcare Economics
In a significant shift in the understanding of diabetes care, last year, the Centers for Medicare & Medicaid Services (CMS) introduced a new coding system that recognizes type 2 diabetes remission. This change, symbolized by the new ICD-10-CM code E11.A, allows healthcare providers to document a patient's successful transition into remission distinctively. For a patient to qualify for this code, they must demonstrate an HbA1c level below 6.5% for at least three months after stopping glucose-lowering medications. While this coding offers novel avenues for clinical documentation, the broader implications for payment systems remain largely unfulfilled.
The Financial Landscape of Diabetes Management
Despite the promising code for diabetes remission, current financial incentives within Medicare and other payment systems do not align with this new goal. In fact, a year after the introduction of E11.A, the reimbursement structures still favor ongoing treatment over remission strategies. For example, while intensive lifestyle programs, like those assessed by the DiRECT trial, show remarkable positivity, Medicare’s coverage remains limited. Medical nutrition therapy is capped at a mere five hours for new patients and then culled down to two hours in subsequent years.
Quality Measurement: A Missed Opportunity
The intricacies of quality measurements further disenfranchise the concept of remission. Programs like HEDIS, Medicare Advantage Star Ratings, and the Merit-Based Incentive Payment System (MIPS) concentrate their scores on managing diabetes rather than rewarding the achievement of remission. With recent adjustments tightening quality measures, healthcare providers are becoming disincentivized to focus on long-term remission outcomes as patients who achieve remission merely drop out of quality measurement calculations, offering no advantage to the healthcare practice.
Shifting the Focus: Why Remission Should Be the Target
With the financial ecosystem primarily designed for chronic management of diabetes, practices aiming to implement diabetic remission strategies face significant hurdles. Currently, investing in remission-focused programs requires upfront costs with very little return on investment, while managing chronic conditions allows for continual payments for visits and medication refills. This creates a counterproductive culture where practices are disincentivized from pursuing the ideal outcome for patients.
A Path Forward: Practical Steps for Concierge Practices
As medical concierge practices aim for excellence in diabetes management, understanding and adapting to these regulatory and financial landscapes is crucial. To thrive, practices can:
Advocate for policy changes that reward and recognize remission outcomes.
Implement comprehensive lifestyle intervention programs that cater to the remission pathway.
Educate both patients and staff on the ongoing shifts in diabetes care definitions and their implications.
By embracing these strategies, medical concierge practices can position themselves not only as leaders in diabetes care but also significantly enhance their operational sustainability.
Write A Comment